Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Solid Tumors Harboring NTRK Fusion
View Full LandscapeTarget Indication
Solid Tumors Harboring NTRK Fusion
Clinical Trial
NCT02576431Last updated: 12/19/2025
No patent data available. Pre-approval drugs may not have Orange Book listings.
Vitrakvi
Vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.
Superficial Vein Thrombosis
Polypoidal Choroidal Vasculopathy
Pelvic Inflammatory Disease
Pulmonary Tuberculosis
Severe Sepsis